Sugi Predict

Sugi Predict / Compounds / SCHEMBL5525017

SCHEMBL5525017

SCHEMBL5525017

OB(O)c1cnc(N2CCOCC2)nc1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.57
▸ KDM4E B2RXH2 2/20 0.47
▸ CNR2 P34972 2/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ TSHR P16473 1/20 0.43
▸ AOC3 Q16853 1/20 0.43
▸ PIK3CA P42336 5/20 0.42
▸ PIK3CD O00329 1/20 0.42
▸ PIK3CB P42338 1/20 0.42
▸ PIK3R1 P27986 4/20 0.41
▸ MTOR P42345 4/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ USP2 O75604 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18007187 0.82 ALDH1A1 (0.38) POLBKDM4EALDH1A1MAPK1TSHR
SCHEMBL3946301 0.82 ALDH1A1 (0.41) POLBALDH1A1MAPK1TSHRHDAC6
SCHEMBL3945544 0.81 POLB (0.42) POLBALDH1A1MAPK1TSHRKMT2A
SCHEMBL10413396 0.79 POLB (0.62) POLBKDM4ECNR2ALDH1A1MAPK1
SCHEMBL2557704 0.78 PTPN11 (0.44) POLBKDM4EALDH1A1MAPK1TSHR
SCHEMBL15330361 0.78 HTR3A (0.46) ALDH1A1MAPK1TSHRKMT2AHDAC6
SCHEMBL16792009 0.78 ALDH1A1 (0.53) KDM4EALDH1A1TSHRHDAC6USP2
SCHEMBL16793545 0.78 PTPN11 (0.38) POLBCNR2ALDH1A1PIK3CAPIK3R1
SCHEMBL29586304 0.77 ALDH1A1 (0.54) POLBKDM4ECNR2ALDH1A1KMT2A
SCHEMBL9147 0.77 ALDH1A1 (0.54) POLBKDM4ECNR2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479849-B2 EGFR inhibitors for the treatment of cancer HOFFMANN-LA ROCHE INC. (US) 2025-11-25 — — US disclosed
EP-4610263-A1 PAN-KRAS INHIBITOR COMPOUND Adlai Nortye Biopharma Co., Ltd. (CN) 2025-09-03 — — EP disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 — — US disclosed
CN-113993872-B EGFR inhibitors for the treatment of cancer 豪夫迈·罗氏有限公司 2024-09-24 — — CN disclosed
CN-115916777-B ATX inhibitor and preparation method and application thereof 苏州爱科百发生物医药技术有限公司 2024-07-12 — — CN disclosed
US-12006316-B2 9H-pyrrolo-dipyridine derivatives UCB Biopharma SRL (BE) 2024-06-11 — — US disclosed
WO-2024104364-A1 PAN-KRAS INHIBITOR COMPOUND 杭州阿诺生物医药科技有限公司 2024-05-23 — — WO disclosed
CN-118047796-A Pan-KRAS inhibitor compound 杭州阿诺生物医药科技有限公司 2024-05-17 — — CN disclosed
CN-117800964-A PI3K/m-TOR inhibitor and application thereof 四川大学 2024-04-02 — — CN disclosed
US-20230295159-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) 2023-09-21 — — US disclosed
US-20070244130-A1 Compounds and Compositions as Ppar Modulators IRM LLC (BM) 2007-10-18 — — US disclosed
US-20070244130-A1 Compounds and Compositions as Ppar Modulators IRM LLC (BM) 2007-10-18 — — US disclosed
US-20070244130-A1 Compounds and Compositions as Ppar Modulators IRM LLC (BM) 2007-10-18 — — US disclosed
US-20070203155-A1 Compounds And Compositions As Ppar Modulators IRM LLC (BM) 2007-08-30 — — US disclosed
US-20070203155-A1 Compounds And Compositions As Ppar Modulators IRM LLC (BM) 2007-08-30 — — US disclosed
US-20070203155-A1 Compounds And Compositions As Ppar Modulators IRM LLC (BM) 2007-08-30 — — US disclosed
EP-1749003-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-02-07 — — EP disclosed
EP-1748993-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2007-02-07 — — EP disclosed
WO-2005116000-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2005-12-08 — — WO disclosed
WO-2005116016-A1 COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS IRM LLC (BM) 2005-12-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 POLB 3553/4885KDM4E 217/4885CNR2 2414/4885
US-20070203155-A1 Compounds And Compositions As Ppar Modulators PPARG, PPARA, PPARD POLB 1094/4885KDM4E 3328/4885CNR2 398/4885
US-12006316-B2 9H-pyrrolo-dipyridine derivatives MAPT, PSEN1, PRNP POLB 522/4885KDM4E 1968/4885CNR2 3909/4885
US-20230295159-A1 ATX INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF ATXN10, GCG, ATXN2L POLB 2655/4885KDM4E 1181/4885CNR2 3485/4885
US-20070244130-A1 Compounds and Compositions as Ppar Modulators PPARG, PPARA, PPARD POLB 1094/4885KDM4E 3328/4885CNR2 398/4885
US-12479849-B2 EGFR inhibitors for the treatment of cancer EGFR, ERBB2, ERBB3 POLB 3795/4885KDM4E 2924/4885CNR2 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.